

Complete Listing of Claims Pursuant to 37 C.F.R. §1.121

Pursuant to 37 C.F.R. §1.121 the following is a complete listing of the claims of the present application. In this set of claims, please amend the claims as follows. Please cancel previously withdrawn claims 16 through 70. With the amendments to the aforementioned claims, the following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (Currently amended) A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human hormone-sensitive lipase (SEQ ID NO: 3), wherein said compound specifically hybridizes with nucleotides 1 through 970 or 1143 through 3775 of said nucleic acid molecule and inhibits the expression of human hormone-sensitive lipase by at least 5% in 80% confluent HepG2 cells in culture at an optimal compound concentration.
2. (Original) The compound of claim 1 which is an antisense oligonucleotide.
3. (Canceled)
4. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. (Original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (Original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. (Original) The compound of claim 8, wherein the modified nucleobase is a 5-methylcytosine.
10. (Original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. (Previously presented) A compound of 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding human hormone-sensitive lipase (SEQ ID NO: 3).

12. (Previously presented) A composition comprising the compound of claim 1 or claim 76 and a pharmaceutically acceptable carrier or diluent.

13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.

14. (Original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.

15. (Previously presented) A method of inhibiting the expression of hormone-sensitive lipase in cells or tissues comprising contacting said cells or tissues with an amount of the compound of claim 1 or claim 76 sufficient to inhibit expression of hormone-sensitive lipase.

16-71. (Canceled)

72. (Previously presented) The compound of claim 1, wherein said compound inhibits the expression of the nucleic acid molecule encoding human hormone-sensitive lipase by at least 15% in 80% confluent HepG2 cells in culture at an optimal compound concentration.

73. (Previously presented) The compound of claim 1, wherein said compound inhibits the expression of the nucleic acid molecule encoding human hormone-sensitive lipase by at least 40% in 80% confluent HepG2 cells in culture at an optimal compound concentration.

74. (Previously presented) The compound of claim 1, wherein said compound inhibits the expression of the nucleic acid molecule encoding human hormone-sensitive lipase by at least 50% in 80% confluent HepG2 cells in culture at an optimal compound concentration.

75. (Previously presented) The compound of claim 1, wherein said compound inhibits the expression of the nucleic acid molecule encoding human hormone-sensitive lipase by at least 60% in 80% confluent HepG2 cells in culture at an optimal compound concentration.

76. (Previously presented) An oligonucleotide mimetic compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human hormone-sensitive lipase (SEQ ID NO: 3), wherein said compound specifically hybridizes with and inhibits the expression of the nucleic acid molecule encoding human hormone-sensitive lipase.

77. (Previously presented) The compound of claim 76 wherein the oligonucleotide mimetic compound comprises at least one modified internucleoside linkage.

78. (Previously presented) The compound of claim 77 wherein the modified internucleoside linkage is a phosphorothioate linkage.

79. (Previously presented) The compound of claim 76 wherein the oligonucleotide mimetic compound comprises at least one modified sugar moiety.

80. (Previously presented) The compound of claim 79 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

81. (Previously presented) The compound of claim 76 wherein the oligonucleotide mimetic compound comprises at least one modified nucleobase.

82. (Previously presented) The compound of claim 81, wherein the modified nucleobase is a 5-methylcytosine.

83. (Previously presented) The compound of claim 76 wherein the oligonucleotide mimetic compound is a chimeric oligonucleotide.